Wells Fargo & Company Sage Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 24,702 shares of SAGE stock, worth $143,518. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,702
Previous 17,322
42.6%
Holding current value
$143,518
Previous $324,000
17.28%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding SAGE
# of Institutions
218Shares Held
47.9MCall Options Held
854KPut Options Held
195K-
Vanguard Group Inc Valley Forge, PA6.42MShares$37.3 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.48MShares$31.8 Million0.99% of portfolio
-
Black Rock Inc. New York, NY5.22MShares$30.3 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.46MShares$25.9 Million0.81% of portfolio
-
State Street Corp Boston, MA2.47MShares$14.4 Million0.0% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $345M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...